Anxiety and Depression Symptoms During CGRP-Targeted Therapy in Patients with Migraine: A Retrospective Cohort Study from the United Arab Emirates.

Anxiety and depression are often seen in people with migraines. This study looked at whether CGRP-targeted therapies help reduce these symptoms. Researchers studied 121 adults in the UAE with migraines and anxiety or depression. They measured anxiety and depression levels before and six months after starting treatment. They used specific questionnaires to evaluate changes. The study found that many patients experienced significant improvements in their anxiety and depression scores. These improvements were linked to a decrease in migraine days for some patients. Researchers also compared different treatments to see which worked best. Overall, the findings suggest that CGRP-targeted therapies may benefit patients beyond just reducing migraines. This could lead to better overall mental health for those suffering from migraines. Clinical relevance: This research indicates that CGRP-targeted therapies may improve anxiety and depression symptoms in migraine patients, potentially enhancing overall treatment outcomes for these individuals.